Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? (Q37998574)

26 August 2017

Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? (English)

1 reference

26 August 2017

1 reference

2

Srdan Verstovsek

1 reference

26 August 2017

Claire Harrison

1

1 reference

26 August 2017

Mary F McMullin

series ordinal

3

1 reference

26 August 2017

Ruben Mesa

series ordinal

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

29 March 2012

1 reference

British Journal of Haematology

26 August 2017

1 reference

26 August 2017

157

1 reference

26 August 2017

4

1 reference

26 August 2017

426-437

1 reference

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

26 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

The myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

EZH2 mutational status predicts poor survival in myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Zwei Fälle von Leukämie mit eigenthümlichem Blut- resp. Knochenmarksbefund

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Jak2 is essential for signaling through a variety of cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

New mutations and pathogenesis of myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09108.X

10.1111/J.1365-2141.2012.09108.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference